Table 1.
Clinical characteristics of the patients
| Patient | Gender | Age at Onset of NS (yr) | Age at the Time of the Study (yr) | No. of Relapses after Last CP | Cumulative CP Dosage (mg/kg) | Height (cm) | BMI (kg/m2) | BP (mmHg) | Current Medications | Duration of CsA Therapy (mo) | Duration of Remission (mo) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 3.0 | 42 | 20 | 248 | 156.5 | 24.5 | 126/80 | Pred, CsA, ena, Ca | 72 | 0.6 |
| 2 | M | 1.2 | 32 | 29 | 412 | 173.5 | 20.2 | 112/70 | Pred | 115 | 0.9 |
| 3 | M | 6.4 | 17 | 7 | 154 | 183.5 | 19.8 | 125/80 | CsA | 109 | 0.4 |
| 4 | M | 2.7 | 28 | 12 | 176 | 174.0 | 22.0 | 130/70 | Pred, FK560, ena | 72 | 14.9 |
| 5 | M | 2.5 | 36 | 41 | 414 | 159.5 | 17.6 | 120/75 | Tri, peri | 66 | 1.6 |
| 6 | M | 2.2 | 32 | 9 | 182 | 183.5 | 31.0 | 120/80 | Pred, CP | 58 | 5.7 |
| 7 | M | 3.0 | 32 | 10 | 129 | 184.0 | 31.4 | 115/70 | - | 7 | 130.0 |
| 8 | M | 3.6 | 20 | 34 | 165 | 175.0 | 22.2 | 140/70 | Pred, CsA, MMF | 135 | 0.1 |
| 9 | M | 7.7 | 23 | 14 | 158 | 200.0 | 22.2 | 155/88 | - | 0 | 17.2 |
| 10 | M | 4.8 | 16 | 18 | 168 | 159.5 | 17.7 | 115/70 | MMF | 28 | 1.6 |
| 11 | M | 3.0 | 42 | Unknown | 334 | 177.0 | 23.5 | 118/80 | Atenolol | 124 | 41.2 |
| 12 | M | 5.0 | 19 | 26 | 168 | 169.0 | 18.8 | 136/64 | CsA, Ca | 144 | 5.0 |
| 13 | F | 2.6 | 18 | 16 | 150 | 172.0 | 19.2 | 110/70 | Pred, tacro, MMF, ena, vitD, Ca | 81 | 0.3 |
| 14 | F | 7.3 | 23 | 30 | Unknown | 162.5 | 20.5 | 120/80 | Pred, los | 148 | 5.7 |
| 15 | F | 2.6 | 26 | >50 | 387 | 175.0 | 25.9 | 138/86 | Pred, CsA | 174 | 33.6 |
Ca, calcium; ena, enalapril; los, losartan; MMF, mycophenolate mofetil; peri, perindopril; pred, prednisone; tacro, tacrolimus; tri, triamcinolone; vitD, vitamin D.